Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients

Relationship between Biodistribution and Tracer Kinetics of <sup>11</sup>C-Erlotinib, <sup>18</sup>F-Afatinib and <sup>11</sup>C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients

Background: Patients with non-small cell lung cancer (NSCLC) driven by activating epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting EGFR, i.e., tyrosine kinase inhibitors (TKI). Radiolabeled EGFR-TKI and PET have been investigated to study EGFR-TKI kinetics...

Full description

Bibliographic Details
Main Authors: Eveline Annette van de Stadt, Maqsood Yaqub, Robert C. Schuit, Imke H. Bartelink, Anke F. Leeuwerik, Lothar A. Schwarte, Adrianus J. de Langen, Harry Hendrikse, Idris Bahce
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Diagnostics
Subjects:
non-small cell lung cancer
EGFR TKI PET/CT
biodistribution
<sup>11</sup>C-erlotinib
<sup>18</sup>F-afatinib
<sup>11</sup>C-osimertinib
Online Access:https://www.mdpi.com/2075-4418/12/4/883

Similar Items

Similar Items